Improved therapeutic performance of dithranol against psoriasis employing systematically optimized nanoemulsomes

References

• Agarwal R, Katare OP, Vyas SP. Preparation and in vitro evaluation of liposomal/niosomal delivery systems for antipsoriatic drug dithranol. Int J Pharm 2001; 228: 43–52
   PubMed Web of Science ®Google Scholar
• Amselem AS, Yogev A, Zawoznik E, Friedman D, 1994. Emulsomes, a novel drug delivery technology, Proceedings of the international symposium on the control and release of bioactive materials, Vol. 21, p. 1369
   Google Scholar
• Bhatia A, Raza K, Singh B, Katare OP. Phospholipid-based formulation with improved attributes of coal tar. J Cosmet Dermatol 2009; 8: 282–88
   PubMed Web of Science ®Google Scholar
• British Pharmacopoeia (BP). 2008. British Pharmacopoeia Commission, Secretariat of Medicines and Healthcare Products Regulatory Agency, London, p. 2641
   Google Scholar
• Cevc G. Transdermal drug delivery of insulin with ultradeformable carriers. Clin Pharmacokinet 2003; 42: 461–74
   PubMed Web of Science ®Google Scholar
• Cuia F, Shia K, Zhanga L, Taoa A, Kawashima Y. Biodegradable nanoparticles loaded with insulin–phospholipid complex for oral delivery: Preparation, in vitro characterization and in vivo evaluation. J Control Rel 2006; 114: 242–50
   PubMed Web of Science ®Google Scholar
• European Pharmacopoeia (Eur Ph 7.0). 2010. European Directorate for the Quality of Medicines, Council of Europe, Strasbourg, France, p. 2110
   Google Scholar
• Fluhr JW, Kuss O, Diepgen T, Lazzerini S, Pelosi A, Gloor M, Berardesca E. Testing for irritation with a multifactorial approach: Comparison of eight non-invasive measuring techniques on five different irritation types. Br J Dermatol 2001; 145: 696–703
   PubMed Web of Science ®Google Scholar
• Ishii F, Nii T. Properties of various phospholipid mixtures as emulsifiers or dispersing agents in nanoparticle drug carrier preparations. Colloids Surf B Biointerfaces 2005; 41: 257–62
   PubMed Web of Science ®Google Scholar
• Katare OP, Raza K, Singh B, Dogra S. Novel drug delivery systems in topical treatment of psoriasis: Rigors and vigors. Indian J Dermatol Venereol Leprol 2010; 76: 612–21
   PubMed Web of Science ®Google Scholar
• Kato A, Ishibashi Y, Miyake Y. Effect of egg yolk lecithin on transdermal delivery of bunazosin hydrochloride. J Pharm Pharmacol 1987; 39: 399–400
   PubMed Web of Science ®Google Scholar
• Kudsi S, Bersaques J De, Geerts ML, Remon JP, Muynck C De. Water-miscible dithranol cream in treatment of psoriasis. J Dermatolog Treat 1991; 2: 19–22
   Google Scholar
• Kumar R, Singh B, Bakshi G, Katare OP. Development of liposomal systems of finasteride for topical applications: Design, characterization, and in vitro evaluation. Pharm Dev Technol 2007; 12: 591–601
   PubMed Web of Science ®Google Scholar
• Lewis GA, Mathieu D, Phan-Tan-Luu R. Pharmaceutical experimental design1st. Marcel Dekker, New York, NY 1999
   Google Scholar
• Mahrle G. Dithranol. Clin Dermatol 1997; 15: 723–37
   PubMed Web of Science ®Google Scholar
• Manjunath K, Reddy JS, Venkateswarlu V. Solid lipid nanoparticles as drug delivery systems. Methods Find Exp Clin Pharmacol 2005; 27: 1–20
   PubMedGoogle Scholar
• Murthy RSR, Umrethia ML. Optimization of formulation parameters for the preparation of flutamide liposomes by 3(3) factorial 26 -terms logit model. Pharm Dev Technol 2004; 9: 1–9
   PubMed Web of Science ®Google Scholar
• Mustakallio KK. Irritation and staining by dithranol (anthralin) and related compounds: I. Estimation with chamber testing and contact thermography. Acta Derm Venereol Suppl (Stockh) 1979; 59: 125–32
   PubMed Web of Science ®Google Scholar
• Mustakalio KK. Irritation, staining and antipsoriatic activity of 10-acyl analogue of anthralin. Br J Dermatol 1981; 105: 23–7
   Web of Science ®Google Scholar
• Prins M, Swinkels OQ, Kolkman EG, Wuis EW, Hekster YA, van der Valk PG. Skin irritation by dithranol cream: A blind study to assess the role of the cream formulation. Acta Derm Venereol 1998; 78: 262–5
   PubMed Web of Science ®Google Scholar
• Raza K, Negi P, Takyar S, Shukla A, Amarji B, Katare OP. Novel dithranol phospholipid microemulsion for topical application: Development, characterization and percutaneous absorption studies. J Microencapsul 2011a; 28: 190–9
   PubMed Web of Science ®Google Scholar
• Raza K, Singh B, Mahajan A, Negi P, Bhatia A, Katare OP. Design and evaluation of flexible membrane vesicles (FMVs) for enhanced topical delivery of capsaicin. J Drug Target 2011b; 19: 293–302
   PubMed Web of Science ®Google Scholar
• Schubert MA, Müller-Goymann CC. Characterisation of surface-modified solid lipid nanoparticles (SLN): Influence of lecithin and nonionic emulsifier. Eur J Pharm Biopharm 2005; 61: 77–86
   PubMed Web of Science ®Google Scholar
• Schwartz JB, Connor RE. Optimization techniques in pharmaceutical formulation and processing. Modern pharmaceutics, GS Banker, CT Rhodes. Marcel Dekker, New York 1996; 727–52
   Google Scholar
• Seth AK, Mishra A, Umrigar D. Topical liposomal gel of idoxuridine for the treatment of herpes simplex: Pharmaceutical and clinical implications. Pharm Dev Technol 2004; 9: 277–89
   PubMed Web of Science ®Google Scholar
• Singh B, Ahuja N. Book review on “Pharmaceutical Experimental Design”. Int J Pharm 2000; 195: 247–48
   Google Scholar
• Singh B, Ahuja N. Development of controlled release bucco-adhesive hydrophilc matrices of diltiazem hydrochloride: Optimization of bioadhesion, dissolution and diffusion parameters. Drug Develop Ind Pharm 2002; 28: 433–44
   Web of Science ®Google Scholar
• Singh B, Dahiya M, Saharan V, Ahuja N. Optimizing drug delivery systems using “Design of Experiments” Part II: Retrospect and Prospects. Crit Rev Ther Drug Carrier Syst 2005a; 22: 215–92
   PubMed Web of Science ®Google Scholar
• Singh B, Kapil R, Nandi M, Ahuja N. Developing oral drug delivery systems using formulation by design: Vital precepts, retrospect and prospects. Expert Opin Drug Deliv 2011; 8: 1341–60
   PubMed Web of Science ®Google Scholar
• Singh B, Kaur S, Ahuja N. Formulation and optimization of controlled release mucoadhesive tablets of atenolol using response surface methodology. AAPS PharmSciTech 2006; 7: E1–10
   PubMedGoogle Scholar
• Singh B, Kumar R, Ahuja N. Optimizing drug delivery systems using “Design of Experiments” Part 1: Fundamental aspects. Crit Rev Ther Drug Carrier Syst 2005b; 22: 27–106
   PubMed Web of Science ®Google Scholar
• Singh B, Mehta G, Kumar R, Bhatia A, Ahuja N, Katare OP. Design, development and optimization of nimesulide-loaded liposomal systems for topical application. Curr Drug Del 2005c; 2: 143–53
   PubMedGoogle Scholar
• Singh B, Pahuja S, Kapil R, Ahuja N. Formulation development of oral controlled release tablets of hydralazine: Optimization of drug release and bioadhesive characteristics. Acta Pharm 2009; 59: 1–13
   PubMed Web of Science ®Google Scholar
• United States Pharmacopeia (USP 34) and the National Formulary (NF 29). 2011. US Pharmacopeial Convention, United States, p. 1536
   Google Scholar
• Vyas SP, Gupta S. Development and characterization of amphotericin B bearing emulsomes for passive and active macrophage targeting. J Drug Target 2007; 15: 206–17
   PubMed Web of Science ®Google Scholar
• Weller PJ, Newman CM, Middleton KR, Wicker SM. Stability of a novel dithranol ointment formulation, containing ascorbyl palmitate as an anti-oxidant. J Clin Pharm Ther 1990; 15: 419–23
   PubMed Web of Science ®Google Scholar